Seek Returns logo

ASND vs. NBIX: A Head-to-Head Stock Comparison

Updated

Here’s a clear look at ASND and NBIX, comparing key factors like performance, valuation metrics, dividends, and financial strength. It’s built for investors or anyone curious to see how these two stocks match up.

Company Overview

With ASND at 9.55 billion USD and NBIX at 11.93 billion USD, their market capitalizations sit in the same ballpark.

ASND’s beta of 0.40 points to much larger expected swings compared to NBIX’s calmer 0.26, suggesting both higher upside and downside potential.

ASND trades as an ADR, giving U.S. investors a simple on-ramp to its foreign shares, while NBIX remains a standard domestic listing.

SymbolASNDNBIX
Company NameAscendis Pharma A/SNeurocrine Biosciences, Inc.
CountryDKUS
SectorHealthcareHealthcare
IndustryBiotechnologyDrug Manufacturers - Specialty & Generic
CEOMr. Jan Moller MikkelsenMr. Kyle W. Gano Ph.D.
Price158.1 USD120.56 USD
Market Cap9.55 billion USD11.93 billion USD
Beta0.400.26
ExchangeNASDAQNASDAQ
IPO DateJanuary 28, 2015May 23, 1996
ADRYesNo

Performance Comparison

This chart compares the performance of ASND and NBIX over the past year by tracking the growth of an initial $10,000 investment in each (starting one year ago).

Hover over the lines to see the investment’s value and total return (%) at specific dates.

Data is adjusted for dividends and splits.

Valuation Metrics Comparison

The section examines key financial ratios to assess the valuation of ASND and NBIX based on earnings, cash flow, sales, and book value. Pay attention to the following notable points where extreme values stand out.

  • ASND posts a negative P/E of -24.55, reflecting last year’s net loss, while NBIX at 39.31 signals healthy earnings.
  • ASND posts a negative forward PEG of -2.23, hinting at anticipated earnings decline, whereas NBIX at 1.35 has projections for stable or growing earnings.
  • ASND has a negative P/B ratio of -44.19, indicating its liabilities exceed assets (negative equity). NBIX, with a P/B of 4.74, maintains positive shareholder equity.
  • ASND has a negative Price-to-Free Cash Flow ratio of -27.43, signaling it consumed more cash than it produced over the last year—an important liquidity warning. In contrast, NBIX (P/FCF 24.24) indicates positive free cash flow generation.
SymbolASNDNBIX
Price-to-Earnings Ratio (P/E, TTM)-24.5539.31
Forward PEG Ratio (TTM)-2.231.35
Price-to-Sales Ratio (P/S, TTM)22.884.95
Price-to-Book Ratio (P/B, TTM)-44.194.74
Price-to-Free Cash Flow Ratio (P/FCF, TTM)-27.4324.24
EV-to-EBITDA (TTM)-35.7422.57
EV-to-Sales (TTM)23.785.05
EV-to-Free Cash Flow (TTM)-28.5024.76

Dividend Comparison

Neither ASND nor NBIX currently pays a dividend yield; this often indicates they are reinvesting earnings for growth, prioritizing long-term expansion over immediate cash returns to shareholders.

SymbolASNDNBIX
Dividend Yield (TTM)0.00%0.00%

Financial Strength Metrics Comparison

This section dives into the financial resilience of ASND and NBIX, spotlighting key metrics like liquidity, leverage, and debt coverage. Check out the standout observations below where notable differences or extremes pop up.

  • ASND’s quick ratio of 0.71 suggests it may struggle to cover immediate liabilities without selling inventory or raising cash, whereas NBIX at 3.02 maintains a comfortable buffer of liquid assets.
  • ASND has negative equity (debt-to-equity ratio -4.46), an unusual warning sign, while NBIX at 0.18 maintains a conventional debt-to-equity balance.
  • ASND has negative EBIT (interest coverage -3.72), unable to cover interest, while NBIX shows “--” (negligible interest expense).
SymbolASNDNBIX
Current Ratio (TTM)1.043.13
Quick Ratio (TTM)0.713.02
Debt-to-Equity Ratio (TTM)-4.460.18
Debt-to-Assets Ratio (TTM)0.800.12
Interest Coverage Ratio (TTM)-3.72--